SUNNYVALE, California, April 10 /PRNewswire/ --
- Attendance Doubles with More Than 200 Health Professionals From 28 Countries Participating
Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that the second European Radiosurgery Workshop yielded record attendance with more than twice the number of attendees compared to the previous year. The event was held March 27-28 at the University Hospital of Charite in Berlin, Germany.
The University Hospital of Charite is one of the oldest hospitals in Germany and among the largest university clinics in Europe with a reputation worldwide for excellence in medicine and research. We were thus very enthusiastic about hosting the second edition of this workshop focused on what is undeniably one of the major innovations in high precision radiosurgery during the last decade, said Professor Volker Budach, M.D., Ph.D., head of the radiation oncology department and president of the German Society for Radiation Oncology.
At this year's workshop, more than 200 attendees from 28 different countries throughout Europe and the Middle East gathered to hear presentations on the latest clinical and technical CyberKnife experiences. Leading experts from Europe and the United States presented studies, some consisting of populations as large as 400 patients, focused on brain, spine, lung, liver, pancreas and prostate. Attendees ranged from radiation oncologists and neurosurgeons to medical physicists and hospital administrators; all interested in learning more about the latest results as well as new approaches in treatment planning and dose delivery.
Highlights included a study presented by Professor Eric Lartigau from Centre Oscar Lambret in Lille, France on the use of CyberKnife radiosurgery to treat head neck cancers. The study, which looked at 46 patients who had failed prior irradiation and were retreated with the CyberKnife, found CyberKnife radiosurgery to be a new, potentially curative therapeutic option with immediate excellent tolerance.
Additionally, J.J. Nuyttens, M.D., from Erasmus MC - Daniel Den Hoed Cancer Center in Rotterdam, The Netherlands, presented experience treating the first 100 of the 200 lung lesions treated at Erasmus using CyberKnife radiosurgery over the past four years. He also highlighted results from a recent study comprising 29 lung cancer patients with central lung tumors, which are traditionally difficult to treat with radiation due to their close proximity to critical structures and organs. Using CyberKnife radiosurgery, the study achieved 88 percent local control with minimal toxicity at 2-years follow-up.
The outstanding quality of presentations and the exceptional number of attendees is clearly a testament to the potential of whole body radiosurgery in Europe. With its unique ability to treat the most complex tumors with unprecedented accuracy, the CyberKnife System raised great interest amongst many clinicians looking for new solutions to treat cancer, said Frederic Sottilini, senior director of marketing, Accuray EMEA.
About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 60,000 patients worldwide and currently more than 155 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical studies, commercialization of products, regulatory review and approval are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading Risk Factors in our report on Form 10-K for the 2008 fiscal year, as updated in our Form 10-Q filed on February 5, 2009 and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.